nach oben

Rheumatology International

Erschienen in:

01.12.2008 | Original Article

Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients

verfasst von: Jadranka Morovic-Vergles, Melanie Ivana Culo, Stjepan Gamulin, Filip Culo

Erschienen in: Rheumatology International | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The relationship between synovial fluid (SF) cAMP level and IL-18 and PGE2 SF levels in rheumatoid arthritis (RA) and osteoarthritis (OA) patients, and between SF cAMP level and disease as well as inflammatory activity in RA were investigated in 17 RA and 19 OA patients. Erythrocyte sedimentation rate (ESR), serum (S) C-reactive protein (CRP) level and SF IL-18 level were higher in RA than in OA patients. SF PGE2 level was similar in both groups. SF cAMP level was higher in OA than in RA patients. In RA patients, SF cAMP level showed negative correlation with Disease Activity Score including a 28-joint count and S CRP, ESR and SF IL-18 level. The results suggest that cAMP promotes anti-inflammatory response in RA and OA patients, which is higher in the latter. Promotion of anti-inflammatory response by cAMP elevating agents might be useful in the treatment of RA.

Weyand CM, Goronzy JJ (2006) Pathomechanisms in rheumatoid arthritis—time for a string theory? J Clin Invest 116:869–871. doi:10.1172/JCI28300 PubMedCrossRef

Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916. doi:10.1056/NEJM200103223441207 PubMedCrossRef

Dayer JM (1999) Interleukin-18, rheumatoid arthritis, and tissue destruction. J Clin Invest 104:1337–1339. doi:10.1172/JCI8731 PubMedCrossRef

Steiner G, Tohidast-Akrad M, Witzmann G et al (1999) Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38:202–213. doi:10.1093/rheumatology/38.3.202 CrossRef

Manicourt DH, Poilvache P, Van Egeren A et al (2000) Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 43:281–288. doi 10.1002/1529-0131(200002)43:2<281::AID-ANR7>3.0.CO;2-7PubMedCrossRef

Yamamura M, Kawashima M, Taniai M et al (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285. doi 0.1002/1529-0131(200102)44:2<275::AID-ANR44>3.0.CO;2-BPubMedCrossRef

Petrovic-Rackov L, Pejnovic N (2006) Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 25:448–452. doi:10.1007/s10067-005-0106-0 PubMedCrossRef

Martel-Pelletier J, Pelletier JP, Fahmi H (2003) Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 33:155–167. doi:10.1016/S0049-0172(03)00134-3 PubMedCrossRef

Hishinuma T, Nakamura H, Sawai T et al (1999) Microdetermination of prostaglandin E2 in joint fluid in rheumatoid arthritis patients using gas chromatography/selected ion monitoring. Prostaglandins Other Lipid Mediat 58:179–186. doi:10.1016/S0090-6980(99)00028-3 PubMedCrossRef

10.

Goto M, Hanyu T, Yoshio T et al (2001) Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 19:377–383PubMed

11.

Bertin P, Lapicque F, Payan E et al (1994) Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol 46:3–7. doi:10.1007/BF00195907 PubMedCrossRef

12.

Seppälä E, Nissilä M, Isomäki H et al (1985) Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol 4:315–320. doi:10.1007/BF02031615 PubMedCrossRef

13.

Elenkov IJ, Wilder RL, Chrousos GP et al (2000) The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52:595–638PubMed

14.

Moore AR, Willoughby DA (1995) The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 101:387–389PubMed

15.

Wadskov S, Donde R, Sylvest J (1979) Plasma and synovial fluid cAMP in patients with rheumatoid arthritis. Scand J Rheumatol 8:136–138. doi:10.3109/03009747909114444 PubMedCrossRef

16.

Trang LE, Lövgren O, Roch-Norlund AE et al (1979) Cyclic nucleotides in joint fluid in rheumatoid arthritis and in Reiter’s syndrome. Scand J Rheumatol 8:91–96. doi:10.3109/03009747909105343 PubMedCrossRef

17.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302 PubMedCrossRef

18.

http://www.das-score.nl/www.das-score.nl/index.html. Accessed 8 Sept 2007

19.

http://www.das-score.nl/www.das-score.nl/dasculators.html. Accessed 8 Sept 2007

20.

Ziolkowska M, Kurowska M, Radzikowska A et al (2002) High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46:1744–1753. doi:10.1002/art.10388 PubMedCrossRef

21.

Fischbach F (1988) Laboratory diagnostic tests, 3rd edn. Lippincott, Philadelphia, pp 57–59

22.

http://www.olympus-diagnostica.com/diagnostica/3112_marketinginformation.cfm. Accessed 8 Sept 2007

23.

http://www.rndsystems.com/pdf/7620.pdf. Accessed 8 Sept 2007

24.

http://www.assaydesigns.com/objects/catalog//product/extras/900-001.pdf. Accessed 8 Sept 2007

25.

http://www.assaydesigns.com/objects/catalog//product/extras/900-067.pdf. Accessed 8 Sept 2007

26.

Dawson B, Trapp RG (2001) Basic and clinical biostatistics, 3rd edn. Lange, New York

27.

Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147–166. doi:10.1016/j.pharmthera.2004.06.003 PubMedCrossRef

28.

Akaogi J, Nozaki T, Satoh M et al (2006) Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 6:383–394PubMed

29.

Min SY, Kim WU, Cho ML et al (2002) Prostaglandin E2 suppresses nuclear factor-kappaB mediated interleukin 15 production in rheumatoid synoviocytes. J Rheumatol 29:1366–1376PubMed

30.

Gomez PF, Pillinger MH, Attur M et al (2005) Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking ofindividual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol 175:6924–6930PubMed

31.

Yacoubian S, Serhan CN (2007) New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat Clin Pract Rheumatol 3:570–579. doi:10.1038/ncprheum0616 PubMedCrossRef

32.

Gabay C (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8 (Suppl 2):S3. doi:10.1186/ar1917

33.

Baumann H, Kushner I (1998) Production of interleukin-6 by synovial fibroblasts in rheumatoid arthritis. Am J Pathol 152:641–644PubMed

34.

Dendorfer U, Oettgen P, Libermann TA (1994) Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 14:4443–4454PubMed

35.

Eigler A, Siegmund B, Emmerich U et al (1998) Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 63:101–107PubMed

36.

Kasyapa CS, Stentz CL, Davey MP et al (1999) Regulation of IL-15-stimulated TNF-alpha production by rolipram. J Immunol 163:2836–2843PubMed

37.

Souness JE, Griffin M, Maslen C et al (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol 118:649–658PubMed

38.

Schillace RV, Carr DW (2006) The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions. Crit Rev Immunol 26:113–131PubMed

39.

Gracie JA, Forsey RJ, Chan WL et al (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104:1393–1401. doi:10.1172/JCI7317 PubMedCrossRef

40.

Taskén K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137–167. doi:10.1152/physrev.00021.2003 PubMedCrossRef

41.

Harris SG, Padilla J, Koumas L et al (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144–150. doi:10.1016/S1471-4906(01)02154-8 PubMedCrossRef

42.

Chen CH, Zhang DH, LaPorte JM et al (2000) Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol 165:5597–5605PubMed

43.

Harizi H, Gualde N (2006) Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol 3:271–277PubMed

44.

Lee JK, Kim SH et al (2004) Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci USA 101:8815–8820. doi:10.1073/pnas.0402800101 PubMedCrossRef

Titel: Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients
verfasst von: Jadranka Morovic-Vergles
Melanie Ivana Culo
Stjepan Gamulin
Filip Culo
Publikationsdatum: 01.12.2008
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 2/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0663-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Factors associated with functional disability in patients with rheumatoid arthritis

Thalassotherapy for fibromyalgia: a randomized controlled trial comparing aquatic exercises in sea water and water pool

Bronchus-associated lymphoid tissue lymphoma in a patient with primary Sjögren’s syndrome

A case report: pregnancy-induced severe osteoporosis with eight vertebral fractures

Dermatomyositis associated with thyroid cancer

Higher LPS-stimulated TNF-α mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with −308G/A polymorphism in promoter region of tumor necrosis factor: association with distinct A33/B58/Cw10 haplotypes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin